Austria
Brazil
Canada
Czech Republic
France
Germany
Hungary
Mauritius
Netherlands
Netherlands OSS
Poland
Spanish Latin America
Spain
Switzerland
China
Japan
Malaysia
Philippines
Taiwan
Ethicare
Fine Chemicals Corporation
Holdings
Beta Healthcare
Kama
Nigeria
ShelysPharmacy News
ANNOUNCEMENT – Aspen Pharmacare – KENACORT back in stock
Aspen Pharmacare Australia Pty Ltd is pleased to announce that KENACORT is back in stock. We anticipate that Kenacort stock will be available through your preferred wholesaler by the middle of November 2020. Download Letter Please wait a moment for the document to load.
Read MoreANNOUNCEMENT – Aspen Pharmacare – SPAN K (potassium chloride) 600 mg tablets x 200 NEW FORMULATION – SUSTAINED RELEASE FILM COATED TABLETS
Aspen Pharmacare Australia Pty Ltd wishes to advise you that after a long period of stock shortages we now have a new film coated formulation of SPAN K 600mg Tabs 200. The new code and EAN will replace the following. Download Letter Please wait a while for the document to load…
Read MoreANNOUNCEMENT – Aspen Pharmacare – ZYBAN SR (Bupropion hydrochloride)150 mg tablets back in stock
Aspen is pleased to inform that ZYBAN SR (Bupropion hydrochloride)150 mg tablets is back in stock after an extended term of supply disruptions and an out of stock situation. Download Letter
Read MoreANNOUNCEMENT – Aspen Pharmacare – SCHEDULE CHANGEMOMASONE(mometasone furoate 0.1%)15 g now changed from Schedule 4 to Schedule 3 medicine
Aspen would like to inform you of the new S3entry for mometasoneas the only therapeutically active substance in preparations for dermal use containing 0.1% or less of mometasone, in packs containing 15 g or less. The effective date is 1 June 2020. Download Letter Please wait a moment for the document to load.
Read MoreANNOUNCEMENT – Aspen Pharmacare – KENACORT Amps 10MG 40MG (INJECTION) – Supply Disruptions
As you may be aware, Aspen Australia is experiencing ongoing supply disruptions affecting the two Kenacort products listed above. Unfortunately, we anticipate that there will be no stock available until further notice. Download Letter Please wait a moment for the document to load.
Read MoreANNOUNCEMENT – Aspen Pharmacare – Levothyroxine supply update- Eutroxsig, Oroxine, and Eltroxin
Aspen Australia has seen a significant increase in demand for certain products due to increased purchasing. Aspen has brought forward manufacturing wherever possible to adjust for the high level of sales experienced in March 2020. To assist you in planning and also for you to provide assurance to your patients, Aspen would like to provide…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Aspen COVID-19 Letter – Potential medicine supply disruptions relating to COVID-19
With the impact of COVID-19 evolving almost daily, including on the manufacturing and transportation of medicines and their ingredients in various countries and on demand within Australia, we assure you that Aspen Australia is in ongoing contact with its suppliers across the world to keep abreast of the situation so we can determine and manage…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Temazepam tablet appearance – colour change
Aspen Australia would like to inform you that due to the removal of the orange dye in the formulation, the appearance of NORMISON and TEMTABS tablets has changed from orange to white in colour. The orange dye is also referred to as “Sunset yellow FCF Aluminium Lake”. Download Letter Please wait a moment for the…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Price Discount: Marcain 0.5% Polyamp DuoFit 50x10mL
Aspen has short dated Marcain 0.5% Polyamp DuoFit 50x10mL (Batch Number 323951, 323952 and 323953) with Expiration Date 30/09/2020 that will be discounted to $215.00 per pack wholesale listed price. This discount offer is only available until 30 June 2020 (unless sold out) on packs with batch number 323951, 323952 or 323953. Download Letter Please…
Read MoreANNOUNCEMENT – Aspen Pharmacare – Ongoing supply disruptions SPAN K (potassium chloride) 600 mg tablets
As per previous communications, Aspen Pharmacare Australia experienced a higher than anticipated demand for SPAN K due to the withdrawal of an alternative product from the market in 2018. Consequently, Aspen is still experiencing supply constraints with Span K as we continue to work on fulfilling the demand. Download Letter Please wait a moment for…
Read More
MAURITIUS 
MENAT 
Nigeria 
South Africa-HOLDINGS 
South Africa-Pharmacare 
Brazil 
Mexico 
USA 
Australia 
New Zealand 
Austria 
Czech Republic 
France 
Netherlands-Aspen API 
Russia 
Slovakia 
SPAIN 
SWITZERLAND 
